162 related articles for article (PubMed ID: 32968870)
1. Cryptococcal meningoencephalitis in a multiple sclerosis patient after fingolimod discontinuation-a case report.
Baghbanian SM; Amiri MRM
Neurol Sci; 2021 Mar; 42(3):1175-1177. PubMed ID: 32968870
[No Abstract] [Full Text] [Related]
2. Cryptococcal meningoencephalitis in an IgG
Wienemann T; Müller AK; MacKenzie C; Bielor C; Weyers V; Aktas O; Hartung HP; Kremer D
BMC Neurol; 2020 Apr; 20(1):158. PubMed ID: 32340606
[TBL] [Abstract][Full Text] [Related]
3. Fingolimod-related cryptococcal meningoencephalitis and immune reconstitution inflammatory syndrome in a patient with multiple sclerosis.
Cuascut FX; Alkabie S; Hutton GJ
Mult Scler Relat Disord; 2021 Aug; 53():103072. PubMed ID: 34139459
[TBL] [Abstract][Full Text] [Related]
4. Cryptococcal meningitis after fingolimod discontinuation in a patient with multiple sclerosis.
Ward MD; Jones DE; Goldman MD
Mult Scler Relat Disord; 2016 Sep; 9():47-9. PubMed ID: 27645342
[TBL] [Abstract][Full Text] [Related]
5. Cryptococcal meningitis in a multiple sclerosis patient treated with Fingolimod: a case report and review of imaging findings.
Chong I; Wang KY; Lincoln CM
Clin Imaging; 2019; 54():53-56. PubMed ID: 30544079
[TBL] [Abstract][Full Text] [Related]
6. Autoimmune hemolytic anemia after treatment with fingolimod in a patient with multiple sclerosis (MS): A case report and review of the literature.
Najdaghi S; Davani DN; Ghajarzadeh M; Shaygannejad V
Autoimmun Rev; 2022 Dec; 21(12):103203. PubMed ID: 36220524
[No Abstract] [Full Text] [Related]
7. Complicated Monkeypox Infection in a Patient With Multiple Sclerosis and Fingolimod Treatment.
Müller-Jensen L; Kriedemann H; Anvari K; Huehnchen P; Siffrin V
Neurology; 2023 Apr; 100(14):670-671. PubMed ID: 36539295
[TBL] [Abstract][Full Text] [Related]
8. Improvement of macular edema without discontinuation of fingolimod in a patient with multiple sclerosis: A case report.
Akiyama H; Suzuki Y; Hara D; Shinohara K; Ogura H; Akamatsu M; Hasegawa Y
Medicine (Baltimore); 2016 Jul; 95(29):e4180. PubMed ID: 27442641
[TBL] [Abstract][Full Text] [Related]
9. Hypothyroidism in multiple sclerosis patient during fingolimod treatment.
Flores J; Rito Y; Torres G; Jung H; Treviño-Frenk I; Corona T
J Neurol Sci; 2015 Jan; 348(1-2):272-3. PubMed ID: 25491264
[No Abstract] [Full Text] [Related]
10. Merkel cell carcinoma in a patient with relapsing-remitting multiple sclerosis treated with fingolimod.
Calvi A; De Riz M; Lecchi E; Pietroboni A; Ghezzi L; Scarioni M; Carandini T; Pellegrinelli A; Maurichi A; Galimberti D; Scarpini E
J Neurol Sci; 2017 Oct; 381():296-297. PubMed ID: 28991701
[No Abstract] [Full Text] [Related]
11. Primary mediastinal large B-cell lymphoma in a patient on Fingolimod for relapsing-remitting multiple sclerosis.
Chacko JA; Strati P; Stout PW; Archer RL; Baltz BP; Chacko JG
Mult Scler Relat Disord; 2021 Apr; 49():102776. PubMed ID: 33508568
[TBL] [Abstract][Full Text] [Related]
12. Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis.
Christopher KL; Elner VM; Demirci H
Ophthalmic Plast Reconstr Surg; 2017; 33(3):e73-e75. PubMed ID: 27533512
[TBL] [Abstract][Full Text] [Related]
13. Unusual adverse dermatologic conditions associated with fingolimod and natalizumab in a patient with relapsing remitting multiple sclerosis.
Mukharesh L; Maloni H; Maiberger M; Chen W; Wallin M
Clin Neurol Neurosurg; 2020 Aug; 195():105886. PubMed ID: 32470781
[No Abstract] [Full Text] [Related]
14. Hepatitis C virus (HCV) reactivation during fingolimod treatment for relapsing and remitting multiple sclerosis.
Tagawa A; Ogawa T; Tetsuka S; Otsuka M; Hashimoto R; Kato H; Ando K; Tanabe H
Mult Scler Relat Disord; 2016 Sep; 9():155-7. PubMed ID: 27645365
[TBL] [Abstract][Full Text] [Related]
15. Kaposi sarcoma in a fingolimod-treated patient with multiple sclerosis.
Walker S; Brew B
J Clin Neurosci; 2016 Sep; 31():217-8. PubMed ID: 27168454
[TBL] [Abstract][Full Text] [Related]
16. Treatment-refractory warts associated with fingolimod.
Sahi N; Al-Araji SA; Ciccarelli O; Chard DT; Trip SA
Pract Neurol; 2022 Dec; 22(6):503-504. PubMed ID: 35981859
[No Abstract] [Full Text] [Related]
17. Fingolimod-associated PML in a patient with prior immunosuppression.
Gyang TV; Hamel J; Goodman AD; Gross RA; Samkoff L
Neurology; 2016 May; 86(19):1843-5. PubMed ID: 27164718
[No Abstract] [Full Text] [Related]
18. Glioblastoma following treatment with fingolimod for relapsing-remitting multiple sclerosis.
Sharim J; Tashjian R; Golzy N; Pouratian N
J Clin Neurosci; 2016 Aug; 30():166-168. PubMed ID: 26970935
[TBL] [Abstract][Full Text] [Related]
19. Approach to Fingolimod-Induced Lymphopenia in Multiple Sclerosis Patients: Do We Have a Roadmap?
Avasarala J; Jain S; Urrea-Mendoza E
J Clin Pharmacol; 2017 Nov; 57(11):1415-1418. PubMed ID: 28543950
[No Abstract] [Full Text] [Related]
20. Virus-related Merkel cell carcinoma complicating fingolimod treatment for multiple sclerosis.
Beadnall HN; Gill AJ; Riminton S; Barnett MH
Neurology; 2016 Dec; 87(24):2595-2597. PubMed ID: 27856777
[No Abstract] [Full Text] [Related]
[Next] [New Search]